

# PATIENT GROUP DIRECTIONS\*

The Supply of Nitrofurantoin 100mg Modified Release Capsules

for the treatment of uncomplicated lower urinary tract infection in women

by Community Pharmacists participating in the

**NHS Cheshire Clinical Commissioning Group** 

Pharmacy First Minor Ailments Service

Version 5

## Date of introduction June 2021

(It is intended that this document will be updated in 2 years subject to no amendments in the interim period )

## Review Date May 2023

### \*HSC 2000/026 Patient Group Directions (England Only)



#### Version Control:

Nitrofurantoin 100mg Modified Release Capsules for the treatment of uncomplicated lower urinary tract infection in women

| Version | Date of introduction | Author                                 | Status   | Comment   |
|---------|----------------------|--|----------|---|
| V1      | November<br>2015     | PGD<br>Development and<br>review group | Approved | To offer nitrofurantoin MR first line to<br>bring community pharmacy service in<br>line with Management of Infection<br>Guidelines. |
| V2      | April 2016           | PGD<br>Development and<br>review group | Draft    | Awaiting development group comment  |
| V2      | April 2016           | PGD<br>Development and<br>review group | Approved | Approved with minor amendments recommended by the PGD subgroup  |
| V3      | April 2017           | PGD<br>Development and<br>review group | Approved | Approved by PGD subgroup on 8<br>Mar 2017   |
| V4      | April 2019           | PGD<br>Development and<br>review group | Approved | Addition of NHS West Cheshire<br>CCG. Updated Patient information<br>leaflet. Approved by PGD<br>subgroup on 12 December 2018.      |
| V5      | April 2021           | PGD<br>Development and<br>review group | Draft    | Updated inclusion criteria; updated<br>TARGET leaflet; updated steering<br>group and CCG signatories                                |
| V5      | April 2021           | PGD<br>Development and<br>review group | Draft    | Pulmonary and neurological conditions added to exclusion criteria   |
| V5      | June 2021            | PGD subgroup                           | Approved | Approved by PGD subgroup on 17<br>Jun 2021  |
|         |                      |  |          |   |
|         |                      |  |          |   |
|         |                      |  |          |   |
|         |                      |  |          |   |



| Patient Group Direction:     | Nitrofurantoin 100mg modified release capsules for the treatment of uncomplicated lower urinary tract infection in women.                        |  |
|------------------------------|--|--|
| Clinical Department/Service: | Community Pharmacists participating in the<br>Pharmacy First Minor Ailments Service commissioned by<br>NHS Cheshire Clinical Commissioning Group |  |

#### 1. Clinical Condition

| 1.1 | Define<br>situation/condition | Uncomplicated lower urinary tract infection in women.  |  |  |
|-----|-------------------------------|--|--|--|
| 1.2 | Criteria for inclusion        | <ul> <li>Treatment should only be provided when there are severe<br/>symptoms or ≥ 2 symptoms from the following list:</li> </ul>            |  |  |
|     |                               | <ul> <li>Dysuria — discomfort, pain, burning, tingling or<br/>stinging associated with urination.</li> </ul>                                 |  |  |
|     |                               | <ul> <li>Nocturia — passing urine more often than usual at<br/>night.</li> </ul>   |  |  |
|     |                               | <ul> <li>Changes in urine appearance or consistency; Urine<br/>may appear cloudy to the naked eye, or change<br/>colour or odour.</li> </ul> |  |  |
|     |                               | <ul> <li>Patient agrees to treatment under this PGD</li> </ul>   |  |  |
| 1.3 | Criteria for exclusion        | <ul> <li>Known hypersensitivity / allergy to nitrofurantoin or any<br/>excipient in the product.</li> </ul>                                  |  |  |
|     |                               | <ul> <li>Treatment either via the pharmacy service or GP within<br/>the previous three months.</li> </ul>                                    |  |  |
|     |                               | <ul> <li>Patients under 18 years of age.</li> </ul>  |  |  |
|     |                               | Patients over 65 years of age.   |  |  |
|     |                               | Haematuria.  |  |  |
|     |                               | Known renal impairment.  |  |  |
|     |                               | Known hepatic impairment.  |  |  |
|     |                               | Known neurological disorders.  |  |  |
|     |                               | Known pulmonary disease.   |  |  |
|     |                               | Pregnant or breast feeding.  |  |  |
|     |                               | Known blood dyscrasias.  |  |  |
|     |                               | Peripheral neuropathy.   |  |  |
|     |                               | <ul> <li>Vaginal itch or unusual discharge.</li> </ul>   |  |  |
|     |                               | <ul> <li>Fever or systemically unwell</li> </ul>   |  |  |



|     |                               | · · · · ·  |
|-----|-------------------------------|--|
|     |                               | Loin pain.   |
|     |                               | Confused or dehydrated.  |
|     |                               | <ul> <li>Patient already taking prophylactic nitrofurantoin.</li> </ul>  |
|     |                               | <ul> <li>Patient recently received oral typhoid vaccine (oral<br/>antibacterials inactivate oral typhoid vaccine).</li> </ul>  |
|     |                               | <ul> <li>Patients taking medicines that may interact e.g. nalidixic<br/>acid or sulfinpyrazone or medicines containing<br/>magnesium salts e.g. magnesium trisilicate (See BNF or<br/>SPC for full list)</li> </ul>  |
|     |                               | <ul> <li>Patients who are anaemic, have diabetes or vitamin B<br/>(particularly folate) deficiency.</li> </ul>   |
|     |                               | Porphyria.   |
|     |                               | G6PD Deficiency (see BNF)  |
| 1.4 | Cautions/additional           | Refer to of Product characteristics.   |
|     | information                   | (http://emc.medicines.org.uk/)   |
| 1.5 | Action if patient<br>excluded | • Patients who do not meet the inclusion criteria for number or severity of symptoms should be advised that cystitis is usually self-limiting and will resolve without antibiotics. Give self care and safety netting advice as contained in the TARGET UTI leaflet at the end of the PGD.   |
|     |                               | • Patients who meet the inclusion criteria for severity or<br>number of symptoms but who are excluded from treatment<br>with nitrofurantoin may be considered for treatment with<br>either pivmecillinam (second line option) or trimethoprim<br>(third line option).  |
|     |                               | • Patients who are excluded from treatment because of signs<br>or symptoms of systemic disease or more serious urinary<br>tract conditions should be referred to GP practice or out of<br>hours via NHS 111 as appropriate. The patient should be<br>provided with a referral note to hand to the GP indicating the<br>reasons for the referral. |
|     |                               | Clearly record the decision on the patient's consultation proforma, advice given and any action taken.   |
| 1.6 | Action if patient declines    | Clearly record the decision on the patient's consultation<br>proforma, including any advice given and any action taken, refer<br>to GP or out of hours via NHS 111 as appropriate.   |

#### 2. Characteristics of staff

| 2.1 | Class of Health<br>Professional for whom<br>PGD is applicable<br>(professional | Qualified Pharmacist registered with the General Pharmaceutical Council (GPhC) |
|-----|--|--|
|-----|--|--|



|     | qualification and training)     |  |
|-----|---------------------------------|--|
| 2.2 | Additional requirements         | <ul> <li>Competent to work under Patient Group Directions, including<br/>satisfactory completion of training to administer /supply in<br/>accordance with this patient group direction</li> </ul>    |
|     |                                 | <ul> <li>Working as a community pharmacist and accredited to<br/>provide the Minor Ailments Service.</li> </ul>  |
| 2.3 | Continued training requirements | <ul> <li>Commitment to continuing updating and re-validation<br/>according to the accreditation requirements of the<br/>commissioning organisation.</li> </ul>                                       |
|     |                                 | <ul> <li>Commitment to keep up to date with clinical developments or<br/>changes to the recommendations for the medicine listed, as<br/>part of their Continual Professional Development.</li> </ul> |

#### 3. Description of Treatment

| 3.1 | Generic name of medicine and form  | Nitrofurantoin 100mg modified release (MR) capsules.   |  |  |
|-----|--|--|--|--|
| 3.2 | Legal status   | РОМ  |  |  |
| 3.3 | Storage  | Room temperature not above 25°C.   |  |  |
| 3.4 | Licensed or unlicensed   | Licensed   |  |  |
| 3.5 | Dose(s)  | 100mg MR twice a day   |  |  |
| 3.6 | Route/Method of<br>Administration  | Oral   |  |  |
| 3.7 | Frequency of administration  | As detailed above (3.5).   |  |  |
| 3.8 | Total dose and number<br>of times treatment can<br>be administered over<br>what time | 100mg MR twice a day. Treatment to be continued for three days<br>Supply 6 capsules.   |  |  |
| 3.9 | Side effects of drugs<br>(including potential<br>Adverse Drug<br>Reaction)           | <ul> <li>Gastrointestinal disturbances including nausea, vomiting and diarrhoea.</li> <li>Acute pulmonary reactions commonly manifested as fever, chills, cough, chest pain. Discontinue treatment.</li> <li>Peripheral neuropathy: Treatment should be stopped at the first signs of neural involvement (paraesthesiae).</li> <li>Hypersensitivity reactions including rashes pruritus and urticaria, angloedema, anaphylaxis, siadenitis.</li> <li>Rarely, cholestatic jaundice, hepatitis, exfoliative dermatitis.</li> </ul> |  |  |



|      |  | Refer to SPC and current BNF for full details.   |  |  |
|------|--|--|--|--|
| 3.10 | Advice/management of adverse reactions/events                | Seek advice from GP practice or out of hours via NHS 111 as appropriate.   |  |  |
| 3.11 | Procedure for reporting<br>Adverse Drug<br>Reactions (ADR's) | • Report serious suspected adverse drug reactions (or all suspected ADRs if the medicine is black triangle) to the Medicines Health and Regulatory Agency using either the yellow cards or via <u>www.yellowcard.gov.uk</u>    |  |  |
|      |  | <ul> <li>Record any adverse drug reaction in the patient's<br/>consultation record and PMR.</li> </ul>   |  |  |
|      |  | Notify patient's GP practice.  |  |  |
| 3.12 | Information on follow up treatment                           | Contact GP practice or out of hours via NHS 111 if symptoms<br>worsen rapidly or significantly at any time, do not start to<br>improve within 48 hours of taking the antibiotic, or the person<br>becomes systemically unwell. |  |  |
| 3.13 | Written/verbal advice for patient/carer                      | Discuss side effects and administration with the patient and provide a manufacturers patient information leaflet.  |  |  |
|      | before/after treatment.                                      | Always complete the full course.   |  |  |
|      |  | Take with food, swallow whole.   |  |  |
|      |  | • Encourage women to maintain hydration by drinking water.   |  |  |
|      |  | <ul> <li>Paracetamol or Ibuprofen may be useful to relieve<br/>pain/discomfort.</li> </ul>   |  |  |
|      |  | <ul> <li>If symptoms do not start to improve within 48 hours of taking<br/>the antibiotic consult your GP.</li> <li>This instruction must be printed on the label.</li> </ul>  |  |  |
|      |  | • If condition recurs within 3 months consult your GP.   |  |  |
|      |  | <ul> <li>Risk of possible STDs should be raised if appropriate.<br/>Sexually active young women with urinary symptoms advise<br/>or offer Chlamydia screening.</li> </ul>  |  |  |
|      |  | May colour urine yellow or brown.  |  |  |
|      |  | • Consult your GP practice if you notice blood in your urine.  |  |  |
|      |  | <ul> <li>May cause dizziness or drowsiness advise patient not to<br/>drive or operate machinery if affected.</li> </ul>  |  |  |
| 3.14 | Specify method of recording supply/                          | The following will be recorded in the patient's consultation proforma:   |  |  |
|      | administration, names of health professional,                | Quantity supplied.   |  |  |



| patient identifiers,              | Advice given to patient.                              |
|-----------------------------------|---|
| sufficient to enable audit trail. | Date of supply.                                       |
|                                   | • The signature of the person supplying the medicine. |



#### 4. Development of the PGD

#### **Multidisciplinary Group:**

The group who have been involved in the development of this PGD included the following people:

| Name                   | Designation  | Signature   | Date      |
|------------------------|--|-------------|-----------|
| Janet Kenyon           | Assistant Director of Medicines<br>Strategy and Optimisation<br>NHS Cheshire Clinical Commissioning<br>Group | J Kenge.    | 8.6.2021  |
| Dr Graham<br>Duce      | GP Prescribing Lead<br>NHS Cheshire Clinical Commissioning<br>Group.   | GMane       | 17.6.2021 |
| Dr Andrew<br>Dunbavand | GP Prescribing Lead<br>NHS Cheshire Clinical Commissioning<br>Group.   | MM.         | 08.7.2021 |
| Suzanne<br>Austin      | Pharmacy Local Professional Network<br>Chair.  | S.B. Austin | 17.6.2021 |
| Susan Nixon            | Minor Ailments Co-ordinator<br>NHS Cheshire Clinical Commissioning<br>Group.                                 | Sne         | 17.6.2021 |
| Dr Ildiko<br>Kustos    | Consultant Medical Microbiologist<br>Countess of Chester Hospital NHS<br>Foundation Trust                    | orkf        | 15.7.2021 |

#### 5. References

- SPC for contraindications and cautions (http://emc.medicines.org.uk/)
- BNF 79 March 2020 September 2020
- RCGP Target leaflet



#### **Responsible Organisation:**

NHS Cheshire Clinical Commissioning Group

#### **Responsibilities of each Organisation:**

Each organisation is required to:

- 1. Approve the contents of this documentation (in the knowledge that it has been prepared by a multidisciplinary group as above).
- 2. Ensure that every PGD is approved and signed by a nominated Senior Pharmacist and Senior Doctor.
- 3. Ensure that the PGD is approved and signed by a senior member of staff, representative of the staff to whom the PGD relates e.g. nurses, chiropodists etc.
- 4. Ensure that the PGD is approved and signed by the Clinical Governance Lead for the Organisation.
- 5. Ensure that individual health professionals working under the direction sign appropriate documentation.



## PATIENT GROUP DIRECTION for the Supply of nitrofurantoin100mg MR capsules for the treatment of uncomplicated lower urinary tract infection in women

| Organisation (s)                          | NHS Cheshire Clinical Commissioning Group   |
|---|---|
| Approved by                               |   |
| Patient Group Direction Subgroup<br>Chair |   |
| Name                                      | Andrea Lunt   |
| Position                                  | Assistant Director of Medicines Strategy and Optimisation<br>& Lead Pharmacist for PGD subgroup<br>NHS Cheshire Clinical Commissioning Group. |
| Signature<br>Date                         | 20.09.2021  |
| Clinical Governance Lead                  |   |
| Name                                      | Dr Andrew McAlavey  |
| Position                                  | Joint Medical Director  |
| Signature                                 | NHS Cheshire Clinical Commissioning Group   |
| Date                                      | LOUN  |
|   | 17.09.21  |

#### NHS Cheshire Clinical Commissioning Group



**TARGET UTI leaflet.** Copies may be printed from https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit//media/85AAD1D4DDEF455A85E0416C3BB714AE.ashx

### TREATING YOUR INFECTION – URINARY TRACT INFECTION (UTI)



🨻 Public Health England

#### For women under 65 years with suspected lower urinary tract infections (UTIs) or lower recurrent UTIs (cystitis or urethritis)

| Possible urinary signs   | & symptoms   | The outcome   | Recommended care   | COVID-19 specific advice   |  |
|--|--|---|--|--|--|
| Kev sians/symptoms;<br>Dysuria: Burning pain when passing urine (wee)<br>New nocturia: Needing to pass urine in the night<br>Cloudy urine: Visible cloudy colour when passing urine<br><u>Other sians/symptoms to consider</u> :<br>Frequency: Passing urine more often than usual<br>Urgency: Feeling the need to pass urine immediately<br>Haematuria: Blood in your urine<br>Suprapublic pain: Pain in your lower tummy |  | Non-pregnant women:<br>If none or only one of: dysuria,<br>new nocturia, cloudy urine;<br>AND/OR vaginal discharge<br>• UTI much less likely<br>• You may need a urine test to check<br>for a UTI<br>• Antibiotics less likely to help<br>• Usually lasts 5 to 7 days | Self-care and pain relief.<br>• Symptoms may get better on their<br>own<br>Delayed or backup prescription<br>with self-care and pain relief<br>Start antibiotics if symptoms:<br>• Get worse<br>• Do not get a little better with<br>self-care within 48 hours | Common symptoms of COVID-19 to look out for are:<br>A loss of, or change to your sense of smell or taste<br>A high temperature<br>A new continuous cough<br>If you have any of these symptoms and think you may<br>have a UTI please do not ignore the UTI symptoms.<br>Book a COVID-19 test and self-isolate for 10 days or<br>until you get a negative test result (www.gov.uk/get-  |  |
| Other things to consider:<br>Recent sexual history<br>Inflammation due to sexual activity can feel<br>similar to the symptoms of a UTI<br>Some sexually transmitted infections (STIs) can<br>have symptoms similar to those of a UTI   |  | If 2 or more of: dysuria, new nocturia,<br>cloudy urine; OR bacteria detected<br>in urine; AND NO vaginal discharge<br>UTI more likely; antibiotics should help<br>• You should start to improve within 48 hours<br>• Symptoms usually last 3 days                    | Immediate antibiotic prescription<br>plus self-care<br>If mild symptoms, delayed or<br>back-up antibiotic prescription<br>plus self-care   | coronavirus-test)     AND     Book a remote / online GP appointment to discuss your     potential UTI and explain that you have also booked a     COVID-19 test.   |  |
| <ul> <li>Changes during menopause</li> <li>Some changes during the meno<br/>symptoms similar to those of a</li> </ul>  | opause can have  | Pregnant women: Always request urine culture If suspected UTI   | Immediate antibiotic<br>prescription plus self-care  | Follow the latest advice on COVID-19 at<br>www.gov.uk/coronavirus and www.nhs.uk   |  |
| Self-care to help yourself<br>get better more quickly  | Optic  | ns to help prevent a UTI  | Antibiotic resistance  | When should you get help?<br>Contact your GP practice or contact NHS   |  |
| <ul> <li>Drink enough fluids to stop<br/>you feeling thirsty. Aim to<br/>drink 6 to 8 glasses</li> </ul>   | Stop bacteria  | to consider these risk factors:<br>spreading from your bowel into your bladder.<br>t (vagina) to back (bottom) after using the toilet.  | Antibiotics can be lifesaving. But<br>antibiotics are not always needed<br>urinary symptoms.   | The following symptoms are possible signs of<br>serious infection and should be assessed<br>urgently.  |  |
| <ul> <li>Avoid too much alcohol, fizzy<br/>drinks or caffeine that can<br/>irritate your bladder</li> </ul>  | <ul> <li>Avoid waiting</li> <li>Go for a wee a<br/>be near the op</li> </ul> | to pass urine. Pass urine as soon as you need to.<br>fter having sex to flush out any bacteria that may<br>ening to the urethra.  | Antibiotics taken by mouth, for any<br>reason, affect our gut bacteria maki  | <u>.</u>   |  |
| <ul> <li>Take paracetamol or ibuprofen<br/>at regular intervals for pain<br/>relief, if you have had no<br/>previous side effects</li> </ul>   | wash away any<br>• Drink enough f  | nal vagina area with water before and after sex to<br>bacteria that may be near the opening to the urethra.<br>uids to make sure you wee regularly throughout the<br>during hot weather.  | some resistant.<br>This may make future UTI more diffi<br>to treat<br>Common side effects to taking  | 1. You have shivering, chills and muscle pain     2. You feel confused, or are very drowsy     cult     3. You have not passed urine all day     4. You are vomiting     5. You see blood in your urine     6. Your temperature is above 38°C* or less than 36°C.  |  |
| There is currently no evidence<br>to support taking cranberry<br>products or cystitis sachets to<br>improve your symptoms     Cranberry prod<br>to say that these<br>After the meno<br>for example, vag  |  | urrent UTI. the following may help<br>oducts and D-mannose: There is some evidence<br>se work to help prevent recurrent UTI<br>opause: Topical hormonal treatment may help;<br>aginal pessaries.  | antibiotics include thrush, rashes,<br>vomiting and diarrhoea. Seek medic<br>advice if you are worried.<br>Keep antibiotics working: only tak  | 7. You have kidney pain in your back just under the<br>ribs<br>8. Your symptoms get worse<br>9. Your symptoms are not starting to improve within<br>4. Hours of this a artifician and international to the starting to the |  |
| <ul> <li>Consider the risk factors in the<br/>'Options to help prevent UTI'<br/>column to reduce future UTIs</li> </ul>  | <ul> <li>Antibiotics at n</li> </ul>   | ight or after sex may be considered   | them when advised by a health<br>professional. This way they are more<br>likely to work for a future UTI.  | *Temperature above 38°C is also a symptom of<br>COVID-19. Please see COVID-19 specific advice.   |  |

Patient Group Directions for supply of Nitrofurantoin 100mg Modified Release Capsules Version 5 Date of first introduction November 2015 Review Date May 2023 Page 11 of 11